

DARZALEX® PATIENTS:

Give this to healthcare professionals **BEFORE** your blood is drawn.

Patient ID document for DARZALEX® (daratumumab)

Name: _____

I am taking the following medication: DARZALEX®, an antibody product for the treatment of multiple myeloma.

Dear Healthcare Professional,

DARZALEX® binds to CD38 on red blood cells (RBCs) and results in a positive Indirect Antiglobulin Test (indirect Coombs test). DARZALEX®-mediated positive indirect antiglobulin test may persist for up to 6 months after the last DARZALEX® infusion. DARZALEX® bound to RBCs masks detection of antibodies to minor antigens in the patient's serum. The determination of a patient's ABO and Rh blood type are not impacted.

You can learn more at <https://www.darzalexhcp.com/sites/www.darzalexhcp.com/files/darzalex-information-on-assay-interference.pdf>.

In case of emergency, or if you find this document, please call the contact listed below:

Doctor, Clinic, Center, or Hospital Name: _____

24-Hour Emergency Telephone Number: _____

